ATI RN
ATI Pharmacology Proctored Exam 2023 Quizlet
1. When taking Digoxin, low levels of what can cause toxicity?
- A. Potassium
- B. Calcium
- C. Sodium
- D. Magnesium
Correct answer: A
Rationale: Low potassium levels can lead to Digoxin toxicity. Digoxin competes with potassium for binding sites on the sodium-potassium pump. When potassium levels are low, there is an increased risk of Digoxin binding and toxicity. Choice B (Calcium) is incorrect because low calcium levels are not directly linked to Digoxin toxicity. Choice C (Sodium) is incorrect as low sodium levels do not cause Digoxin toxicity. Choice D (Magnesium) is incorrect as low magnesium levels do not contribute to Digoxin toxicity.
2. A client has a new prescription for Valsartan, and a nurse is providing discharge teaching. Which of the following instructions should the nurse include?
- A. Take this medication with food.
- B. Avoid potassium-rich foods.
- C. Expect to feel drowsy.
- D. Monitor your blood pressure daily.
Correct answer: D
Rationale: Monitoring blood pressure daily is crucial for clients taking Valsartan, an angiotensin II receptor blocker, to ensure effective management of hypertension. Valsartan helps lower blood pressure by relaxing blood vessels, and regular monitoring helps track the medication's effectiveness and any potential side effects. Choices A, B, and C are incorrect because Valsartan does not need to be taken with food, avoiding potassium-rich foods is not specifically required for this medication, and feeling drowsy is not a common side effect of Valsartan.
3. A nurse is teaching a client who has a new prescription for Hydralazine. Which of the following adverse effects should the nurse instruct the client to monitor?
- A. Tachycardia
- B. Hyperglycemia
- C. Hyponatremia
- D. Constipation
Correct answer: A
Rationale: Corrected Rationale: Hydralazine is a vasodilator that can cause reflex tachycardia as an adverse effect. The client should monitor their pulse and report any significant increases. Choice B, Hyperglycemia, is not a common adverse effect of Hydralazine. Choice C, Hyponatremia, and Choice D, Constipation, are also not typically associated with Hydralazine use.
4. A client has a new prescription for Filgrastim to treat neutropenia. Which of the following statements should the nurse include?
- A. This medication will help increase your white blood cell count.
- B. This medication will help reduce your risk of infection.
- C. This medication will help improve your red blood cell count.
- D. This medication will help increase your platelet count.
Correct answer: A
Rationale: The correct statement the nurse should include is that 'This medication will help increase your white blood cell count.' Filgrastim is a medication used to stimulate the production of white blood cells, specifically neutrophils, to increase the white blood cell count. This increase in white blood cells helps reduce the risk of infections in clients with neutropenia. Choices B, C, and D are incorrect because Filgrastim specifically targets white blood cells, not red blood cells or platelets.
5. When administering medications to a 4-month-old infant, which of the following pharmacokinetic principles should be considered? (Select all that apply.)
- A. Infants have a more rapid gastric emptying time.
- B. Infants have immature liver function.
- C. Infants' blood-brain barrier is poorly developed.
- D. Infants have an increased ability to absorb topical medications.
Correct answer: B
Rationale: When administering medications to a 4-month-old infant, the pharmacokinetic principle to consider is that infants have immature liver function until 1 year of age. This requires medications metabolized by the liver to be administered in smaller dosages. While infants do have a more rapid gastric emptying time, immature liver function is a more critical pharmacokinetic consideration in this context. Additionally, although infants have a poorly developed blood-brain barrier, this relates more to pharmacodynamic effects rather than pharmacokinetic principles. The statement about infants having an increased ability to absorb topical medications is not directly related to pharmacokinetic principles, making choice B the correct answer.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access